Nitric oxide in patients with chronic liver diseases

Romanian Journal of Gastroenterology

Volumn 14, Issue 3, 2005, Pages 225-230

  Pârvu, Alina Elena ^a   Negrean, Vasile ^a   Pleşca Manea, Luminiţa ^a   Cosma, Angela ^a   Drǎghici, Anton ^a   Uifǎlean, Ana ^a   Moldovan, Remus ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Alcoholic; Chronic active hepatitis; Cirrhosis; Nitric oxide; Portal hypertension; Viral etiology

Indexed keywords

CITRULLINE; NITRATE; NITRIC OXIDE; NITRITE;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; BLOOD ANALYSIS; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; MALE; METABOLITE; PATHOGENESIS;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HEPATITIS, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER CIRRHOSIS, ALCOHOLIC; MALE; MIDDLE AGED; NITRIC OXIDE; SEVERITY OF ILLNESS INDEX;

EID: 27144498918     PISSN: 12214167     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Pârvu AE, Pârvu M, Pleşca-Manea L. Efectele inducerii sintezei de oxid nitric asupra organismului. Clujul Med 2003; 3: 537-542.
2. Kirkali G, Gezer S, Umur N, Ozcan MA, Tankurt E. Nitric oxide in chronic liver disease. Turk J Med Sci 2000; 30: 511-515.
3. Farzaneh-Far R, Moore K. Nitric oxide and the liver. Liver 2001; 21: 161-174.
4. Nagral A, Patch D, Burroughs AK. Portal hemodynamics in chronic liver disease. Indian J Gastroenterol 1999; 18: 78-83.
5. Hon WM, Lee KH, Khoo HE. Nitric oxide in liver diseases: friend, foe, or just passerby? Ann N Y Acad Sci 2002; 962: 275-95.
6. Shah V, Lyford G, Gores G, Farrugia G. Nitric oxide in gastrointestinal health and disease. Gastroenterol 2004; 126: 903-913.
7. Taylor BS, Alarcon LH, Billiar TR. Inducible nitric oxide synthase in the liver: regulation and function. Biochemistry (Mosc) 1998; 63: 766-781.
8. Bosch J, Garcia-Pagan JC. Complications of cirrhosis. I. Portal hypertension. J Hepatol. 2000; 32(1 Suppl): 141-156.
9. Yu Q, Shao R, Qian HS, George SE, Rockey DC. Gene transfer of the neuronal NO synthase isoform to cirrhotic rat liver ameliorates portal hypertension. J Clin Invest 2000; 105: 741-748.
10. Fiorucci S, Antonelli E, Tocchetti P, Morelli A. Treatment of portal hypertension with NCX-1000, a liver-specific NO donor. A review of its current status. Cardiovas Drugs Rev 2004; 22: 135-146.
11. Shah V, Cao S, Hendrickson H, Yao J, Katusic S. Regulation of hepatic eNOS by caveolin and calmodulin after bile duct ligation in rats. Am J Physiol Gastrointest Liver Physiol 2001; 280: G1209-G1216.
12. Dudenhoefer AA, Loureiro-Silva MR, Cadelina GW, Gupta T, Groszmann RJ. Bioactivation of nitroglycerin and vasomotor response to nitric oxide are impaired in cirrhotic rat livers. Hepatology 2002; 36: 381-385.
13. Wattanasirichaigoon S, Gordon FD, Resnick RH. Hyperdynamic circulation in portal hypertension: a comparative model of arterio-venous fistula. Med Hypotheses 2000; 55: 77-87.
14. Cahill PA, Redmond EM, Sitzmann JV. Endothelial dysfunction in cirrhosis and portal hypertension. Pharmacol Ther 2001; 89: 273-293.
15. Genesca J, Gonzalez A, Segura R et al. Interleukin-6, nitric oxide, and the clinical and hemodynamic alterations of patients with liver cirrhosis. Am J Gastroenterol 1999; 94: 169-77
16. Genesca J, Segura R, Gonzalez A et al. Nitric oxide may contribute to nocturnal hemodynamic changes in cirrhotic patients. Am J Gastroenterol 2000; 95: 1539-1544.
17. Arkenau HT, Stichtenoth DO, Frolich JC, Manns MP, Boker KH. Elevated nitric oxide levels in patients with chronic liver disease and cirrhosis correlate with disease stage and parameters of hyperdynamic circulation. Z Gastroenterol 2002; 40: 907-913.
18. Blendis L, Wong F. The hyperdynamic circulation in cirrhosis: an overview. Pharmacol Ther 2001; 89: 221-231.
19. Henriksen JH, Kiszka-Kanowitz M, Bendtsen F. Review article: volume expansion in patients with cirrhosis. Aliment Pharmacol Ther 2002; 16 Suppl 5: 12-23.
20. Schmandra TC, Folz IC, Kimpel M, Fleming I, Holzer K, Hanisch EW. Cirrhosis induces a nitric oxide-associated vascular hyporeactivity of aortic segments from healthy rats in vitro. Eu J Gastroent & Hepatol 2001; 13: 957-962.
21. Delclaux C, Mahut B, Zerah-Lancner F et al. Increased nitric oxide output from alveolar origin during liver cirrhosis versus bronchial source during asthma. Am J Respir Crit Care Med 2002; 165: 332-337.
22. Sansoe G, Silvano S, Mengozzi G et al. Systemic nitric oxide production and renal function in nonazotemic human cirrhosis: a reappraisal. Am J Gastroenterol 2002; 97: 2383-2390.
23. Garcia-Estan J, Ortiz MC, Lee SS. Nitric oxide and renal and cardiac dysfunction in cirrhosis. Clin Sci (Lond) 2002; 102: 213-222.
24. Gentilini P, Vizzutti F, Gentilini A, La Villa G. Ascites and hepatorenal syndrome. Eur J Gastroenterol Hepatol 2001; 13: 313-316.
25. Gentilini P, La Villa G, Casini-Raggi V, Romanelli RG. Hepatorenal syndrome and its treatment today. Eur J Gastroenterol Hepatol 1999; 11: 1061-1065.
26. Liu H, Ma Z, Lee SS. Contribution of nitric oxide to the pathogenèsis of cirrhotic cardiomyopathy in bile duct-ligated rats. Gastroenterology 2000; 118: 937-944.
27. Nelson RS, Eichinger MR. Role of nitric oxide (NO) in pulmonary dysfunction associated with experimental cirrhosis. Respir Physiol 2001; 126: 65-74.
28. Piscione F, Manganiello V, Viola O, Chiariello M. Morphologic and functional abnormalities of the cardiovascular system in patients with hepatic cirrhosis. Ital Heart J 2003; 4 Suppl.: 85-95.
29. Robert V, Chabot F, Vial B, Guiot P, Poussel JF, Polu JM. (Hepatopulmonary syndrome: physiopathology of impaired gas exchange). Rev Mal Respir 1999; 16: 769-779.
30. Moller S, Henriksen JH. Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart 2002; 87: 9-15.
31. Hardikar W. Ascites and encephalopathy in chronic liver disease. Indian J Pediatr 2002; 69: 169-173.
32. Szanto P. Nitric oxide in hepatic pathophysiology. Clujul Med 2001; 1-2: 20-26.
33. Schweyer S, Mihm S, Radzun HJ, Hartmann H, Fayyazi A. Liver infiltrating T lymphocytes express interferon gamma and inducible nitric oxide synthase in chronic hepatitis C virus infection. Gut 2000; 46: 255-259.
34. Kandemir O, Polat A, Kaya A. Inducible nitric oxide synthase expression in chronic viral hepatitis and its relation with histological severity of disease. J Viral Hepat 2002; 9: 419-923.
35. Jungersten L, Edlund A, Petersson AS, Wennmalm A. Plasma nitrate as an index of nitric oxide formation in man: analyses of kinetics and confounding factors. Clin Physiol 1996; 16: 369-379.
36. Miranda KM, Espey MG, Wink DA. A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide 2001; 5: 62-71.
37. Boyde TCR, Rahmatullah M. Optimization of conditions for the colorimetric determination of citrulline, using diacetyl monooxime. Anal Biochem 1980; 107: 424-431.
38. George M, Baluch M, Van Thiel DH. Plasma and hepatic tissue levels of thrombomodulin, tissue factor, NFkappaB and nitric oxide in responders and nonresponders to IFNalpha therapy. J Viral Hepat 2003; 10: 360-366.
39. Okamoto T, Yamamura K, Hino O. Expression of the inducible form of the nitric oxide synthase gene in the livers of mice with chronic hepatitis. Int J Mol Med 2000; 6: 315-317.
40. Moussa YI, Plevris JN, Hayes PC. Plasma nitrites/nitrates in HCV infection and hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2000; 12: 159-163.
41. Bakaar G, Sorbi D, Mazzoccoli V. Nitric oxide and chronic HCV and HIV infections. Dig Dis Sci 2001; 46: 1072-1076.
42. Sanchez-Rodriguez A, Criado M, Rodriguez-Lopez AM, Esteller A, Martin de Arriba A, Lopez-Novoa JM. Increased nitric oxide synthesis and inducible nitric oxide synthase expression in patients with alcoholic and non-alcoholic liver cirrhosis. Clin Sci (Lond) 1998; 94: 637-643.
43. Barak N, Zemel R, Ben-Ari Z, Braun M, Tur-Kaspa R. Nitric oxide metabolites in decompensated liver cirrhosis. Dig Dis Sci 1999; 44: 1338-1341.
44. de Lucas S, Bartolome J, Amaro MJ, Carreno V. Hepatitis C virus core protein transactivates the inducible nitric oxide synthase promoter via NF-kappaB activation. Antiviral Res 2003; 60: 117-124.
45. Oekonomaki E, Notas G, Mouzas IA, et al. Binge drinking and nitric oxide metabolites in chronic liver disease. Alcohol Alcohol 2004; 39: 106-109.
46. Wang X, Zhong YX, Zhang ZY et al. Effect of L-NAME on nitric oxide and gastrointestinal motility alterations in cirrhotic rats. World J Gastroenterol 2002; 8: 328-332.